MANAGING GLAUCOMA:.

Slides:



Advertisements
Similar presentations
CD Week 22: Patient compliance “An action in obedience to another request” COMPLIANCE IS A MAJOR HEALTH PROBLEM!
Advertisements

10 Points to Remember on An Effective Approach to High Blood Pressure ControlAn Effective Approach to High Blood Pressure Control Summary Prepared by Debabrata.
Introduction. Adult ADHD in the Real World: From Clinical Trials to Clinical Practice.
Case-Based Examination of Treatment Options in Type 2 Diabetes Management.
Upfront Combination Therapy vs Step-Up Approach for PAH:
Optimizing Combination Endocrine Therapy in HR-Positive Advanced Breast Cancer.
Glaucoma.
Psoriatic Arthritis.
RESISTANT HYPERTENSION OR POOR PATIENT ADHERENCE? TIPS TO GAIN CONTROL
Making Decisions With Your Osteoarthritis Patients
Gout Management.
Glaucoma Progression.
Access to NOAC Therapy:
UNDERSTANDING RISK STRATIFICATION IN PAH:
Motor Fluctuations in Parkinson Disease: Options and Strategies
Migraine Prevention Therapy: Avoiding Overuse of Medications
Modern Strategies for Basal Insulin Use in T2D
Pediatric Antiepileptic Treatment Strategies
COPD Management.
The Latest Data on Oral Prostacyclin Therapy in PAH
How to Achieve Aggressive BP Goals in Difficult-to-Treat Patients
Optimizing Outcomes in the Management of GIST
Resistant Hypertension
Before and After: Patient Cases in Onychomycosis
Clinical Cases in Glaucoma Treatment
All About PAH:.
Strategies to Improve Adherence and Persistence in the Treatment of Hypertension.
The Resurgence of Topical Treatments Across a Spectrum of Psoriasis
Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.
Hypertension Guidelines
How Effective Is Fixed-Dose Combination Therapy in T2D and Where Does It Fit?
PAH in Adults CHEST Guideline and Expert Panel Report: Grading of Evidence
Glaucoma: Detect, Diagnose, And Monitor The Silent Thief of Vision
Introduction. A Reality Check on BP Goals and Optimizing Patient Adherence to Treatment.
Access to NOAC Therapy:
Program Goals. Treatment-Naive Patients With PAH What Do We Know and What Choices Do We Have?
Consensus on Glaucoma Control
Expert Insights Into What's Hot in Glaucoma
Exploring Personalized Prophylaxis in Hemophilia A
Examining the Latest Evidence in PAH
A Primer on Medication Delivery Systems in COPD Management
Current and Future Perspectives on Migraine Prevention Therapy
The Importance of Getting the Dose Right in HF
Translating the Latest and Greatest Advances in PAH Into Clinical Practice.
Navigating Treatment Options in PAH
Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?
A Primer on Medication Delivery Systems in COPD Management
PAH and Prostacyclin Pathways in Focus
When Is Intrathecal Drug Delivery Appropriate?
Optimizing Insulin Therapy in Primary Care: Basal Plus Incretin Combinations.
PAH Treatment.
Clinical Pearls on Hot Topics in MS
What's New in PAH?.
A Guideline-Based Approach to HCV Care
Critical Decision Points in Insomnia
Etiology and Incidence Pathophysiology Hemophilia is due to a defect in thrombin generation on the platelet surface.
This program will include a discussion of off-label treatment and investigational agents not approved by the Food and Drug Administration for use in the.
Patient Stories in PAH: Sequential Therapy in a FC II Patient
Program Goal. Program Goal Disclaimer Overview.
Therapy for Pulmonary Arterial Hypertension in Adults
Managing Pain in the 21st Century
When Is Intrathecal Drug Delivery Appropriate?
Prostacyclin Pathway Agents in Action
Binge Eating Disorder.
Uptitration of Medications in HF: Start Low but Aim High and Stay High
Real-World Data in Cardiology: Focus on Atrial Fibrillation
Merging the Art and Science of Managing nOH in Clinical Practice
What's New in PAH?.
NAFLD and NASH in Europe and Canada
Ask the Psoriasis Expert
Presentation transcript:

MANAGING GLAUCOMA:

EGS Guidelines: Treatment Algorithm

Monotherapy Treatment Options

Summary: Monotherapy Options

Topical Therapy: Be Realistic!

Treatment in the OHTS

EGS Guidelines: Treatment Algorithm

Adherence Decreases With Additional Medications

Drug Absorption With Multiple Dosing

What Is the Evidence?

Pharmacological Preparation of Fixed-Dose Combinations

Fixed Vs Concomitant Unfixed Glaucoma Treatment on Adherence and Ocular Surface Health

FCs in Use

Why Is It Important to Have a FC Without a Beta-Blocker?

Managing Contraindications

Compliance and Long-Term Burden

FCs Vs Concomitant Therapy

24-Hour Control Using FCs

Concluding Remarks

Abbreviations